NK- and T-cell lymphoma - historical

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main NKTCL page for current regimens.

1 regimens on this page 1 variants on this page

Relapsed or refractory

Pembrolizumab monotherapy

Regimen

Study	Evidence
Kwong et al. 2017	Case series

Note: prospective trials are underway.

Immunotherapy

• Pembrolizumab (Keytruda) 2 mg/kg IV once on day 1

21-day cycles

References

1. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed